Our Research

Discover our recent findings, catch up with news, and review in-depth resources and case studies.

Connect with Resolian at these upcoming events.

Optimizing Peptide Permeability Assays: Insights from Our GRC 2025 Poster Presentation

Optimizing Peptide Permeability Assays

Our work, presented at GRC 2025, focuses on overcoming the analytical and biological hurdles associated with peptide permeability testing. The MDCK-MDR1 cell model is a well-established system for evaluating P-glycoprotein (P-gp)-mediated transport, commonly used for small molecules. But peptides, due to their high molecular weight, lipophilicity, and strong intracellular binding, require a more nuanced approach.
Read more

Building a Comprehensive Response to Client Needs as a CRO

In today’s competitive drug development landscape, contract research organizations (CROs) face mounting pressure to deliver more than just scientific expertise. Success requires a multifaceted approach that combines global reach, consistent delivery, technological innovation, and unwavering client focus.
Read more

Resolian Fordham UK LCMS Bioanalytical Lab Tour

Ever wondered what happens to your samples once they reach our laboratory? Take an exclusive behind-the-scenes look at the complete sample journey through our state-of-the-art Fordham facility in Cambridgeshire, UK.
Read more

Resolian Brisbane Australia Bioanalytical Lab Tour

Take a virtual tour of Resolian’s Brisbane bioanalytical laboratory. Located in the center of Brisbane, Australia, Resolian Bioanalytics is a purpose-built bioanalytical laboratory that can provide comprehensive service to support pre-clinical and clinical studies in Australia and worldwide.
Read more

Resolian Malvern USA Bioanalytical Lab Tour

Take a virtual tour of Resolian’s Malvern bioanalytical laboratory – where our expert scientists deliver high-quality data to support nonclinical and clinical trials.
Read more

The Australia Advantage

Did you know that you can start Phase I trials in Australia without an IND? That’s just one of several strategic benefits biotechs are leveraging to speed up development timelines and reduce costs—while generating globally accepted data. In this article, we break it down.
Read more
Scroll to Top

Bioanalysis of Cannabinoids

Biomarker assays established for your specific context of use.

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.